Lactoferrin and iron deficiency anemia in pregnancy

This is the claim with the most direct human evidence behind it, and the evidence base is still only four trials.

What was tested

The comparison is between daily oral bovine lactoferrin and daily oral ferrous iron preparations, usually ferrous sulfate, in pregnant women already diagnosed with iron deficiency anemia. The primary outcome in the pooled analysis was change in hemoglobin at four weeks.

Four randomized trials met the inclusion criteria, covering 600 women in total.

What was found

Pooled across all four trials, hemoglobin change at four weeks favored lactoferrin over ferrous sulfate by a mean difference of 0.77 g/dL, with a 95% confidence interval of 0.04 to 1.55 and a p value of 0.04.

That confidence interval is worth looking at directly. Its lower bound sits at 0.04, barely clear of no difference at all. A result that only just excludes zero is a weak result, whatever the p value beside it says.

The subgroup analysis is more revealing than the headline. Separated by severity, no significant difference appeared between the two treatments in mild anemia across three trials and 372 women. The significant advantage was confined to moderate anemia, and came from a single trial of 228 women.

Gastrointestinal side effects were significantly less frequent with lactoferrin. No significant differences appeared for serum ferritin and iron, preterm birth, low birthweight, neonatal death or mean birthweight.

How to read this

The defensible summary is that oral bovine lactoferrin performs comparably to ferrous sulfate for correcting iron deficiency anemia in pregnancy, and is better tolerated. Tolerability matters more than it sounds: iron supplementation frequently fails because people stop taking it, and the reason they stop is usually the digestive effects.

The grade is Supported rather than Established because four trials totaling 600 women is a thin base, because the pooled effect is fragile, and because the trials were conducted in a narrow set of settings. A larger trial could move this grade in either direction, which is precisely what happened to the preterm infant claim.

The meta-analysis authors went further than this site does, concluding that lactoferrin should be the iron replacement agent of choice in pregnancy. That is a recommendation rather than a finding, and it rests on the same four trials.